Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;97(9):1641-1648.
doi: 10.1016/j.mayocp.2022.06.015. Epub 2022 Jun 23.

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019

Raymund R Razonable  1 , John C O'Horo  2 , Douglas W Challener  2 , Lori Arndt  2 , Richard F Arndt  2 , Caroline G Clune  2 , Tracy L Culbertson  2 , Scott T Hall  2 , Alexander Heyliger  2 , Tammy A Jackson  2 , Brian D Kennedy  2 , Jennifer Larsen  2 , Sara N Hanson  2 , Perry W Sweeten  2 , Sidna M Tulledge-Scheitel  2 , Ravindra Ganesh  2
Affiliations

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019

Raymund R Razonable et al. Mayo Clin Proc. 2022 Sep.

Abstract

Objective: To describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab treatment of mild to moderate coronavirus disease 2019 (COVID-19) during the severe acute respiratory coronavirus 2 (SARS-CoV-2) B.1.617.2 Delta surge.

Methods: This is a retrospective study of high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 between August 1, 2021, and December 1, 2021. Rates of severe disease, hospitalization, intensive care unit admission, and death were assessed.

Results: Among 10,775 high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab for mild to moderate COVID-19 during the Delta surge, 287 patients (2.7%) developed severe disease that led to hospitalization, oxygen supplementation, or death within 30 days after treatment. The rates of severe disease were low among patients treated with bamlanivimab-etesevimab (1.2%), casirivimab-imdevimab (2.9%), and sotrovimab (1.6%; P<.01). The higher rate of severe outcomes among patients treated with casirivimab-imdevimab may be related to a significantly lower COVID-19 vaccination rate in that cohort. Intensive care unit admission was comparable among patients treated bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab (1.0%, 1.0%, and 0.4%, respectively).

Conclusion: This real-world study of a large cohort of high-risk patients shows low rates of severe disease, hospitalization, intensive care unit admission, and mortality after treatment with bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 during the SARS-CoV-2 Delta surge.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Chen P., Nirula A., Heller B., et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with COVID-19. N Engl J Med. 2021;384(3):229–237. - PMC - PubMed
    1. Gottlieb R.L., Nirula A., Chen P., et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644. - PMC - PubMed
    1. Gupta A., Gonzalez-Rojas Y., Juarez E., et al. Early treatment for COVID-19 with SARS-CoV-2 neutralizing antibody sotrovimab. N Engl J Med. 2021;385(21):1941–1950. - PubMed
    1. An EUA for bamlanivimab-A monoclonal antibody for COVID-19. JAMA. 2021;325(9):880–881. - PubMed
    1. An EUA for casirivimab and imdevimab for COVID-19. Med Lett Drugs Ther. 2020;62(1614):201–202. - PubMed

Supplementary concepts